Vile R - Search Results

1

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. Comins C, et al. Among authors: vile r. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6. Clin Cancer Res. 2010. PMID: 20926400 Free PMC article. Clinical Trial.

2

Gene therapy for cancer--managing expectations.

Melcher AA, Garcia-Ribas I, Vile RG. Melcher AA, et al. Among authors: vile rg. BMJ. 1997 Dec 13;315(7122):1604-7. doi: 10.1136/bmj.315.7122.1604. BMJ. 1997. PMID: 9437283 Free PMC article. Review. No abstract available.

3

Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Melcher A, et al. Among authors: vile rg. Cancer Res. 1999 Jun 15;59(12):2802-5. Cancer Res. 1999. PMID: 10383135

4

Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery.

Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JS. Harrington KJ, et al. Among authors: vile rg. Clin Cancer Res. 2000 Jun;6(6):2528-37. Clin Cancer Res. 2000. PMID: 10873109

5

Transcriptional control: an essential component of cancer gene therapy strategies?

Harrington KJ, Linardakis E, Vile RG. Harrington KJ, et al. Among authors: vile rg. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):167-84. doi: 10.1016/s0169-409x(00)00093-4. Adv Drug Deliv Rev. 2000. PMID: 11072113 Review.

6

Cancer gene therapy: developments to 2000.

Bateman AR, Harrington KJ, Melcher AA, Vile RG. Bateman AR, et al. Among authors: vile rg. Expert Opin Investig Drugs. 2000 Dec;9(12):2799-813. doi: 10.1517/13543784.9.12.2799. Expert Opin Investig Drugs. 2000. PMID: 11093354 Review.

7

Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.

Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Higuchi H, et al. Among authors: vile rg. Cancer Res. 2000 Nov 15;60(22):6396-402. Cancer Res. 2000. PMID: 11103804

8

Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.

Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS. Harrington KJ, et al. Among authors: vile rg. Clin Cancer Res. 2000 Dec;6(12):4939-49. Clin Cancer Res. 2000. PMID: 11156255

9

Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.

Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS. Harrington KJ, et al. Among authors: vile rg. Clin Cancer Res. 2001 Feb;7(2):243-54. Clin Cancer Res. 2001. PMID: 11234875

10

Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model.

Harrington KJ, Rowlinson-Busza G, Uster PS, Vile RG, Peters AM, Stewart JS. Harrington KJ, et al. Among authors: vile rg. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1141-8. doi: 10.1016/s0360-3016(00)01444-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240257

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters